Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
ILR-C5251 | Cynomolgus | Cynomolgus IL-23 R Protein, Fc Tag |
|
||
ILR-H82F3 | Human | Biotinylated Human IL-23 R Protein, Fc,Avitag™ (MALS verified) |
|
||
ILR-H5254 | Human | Human IL-23 R Protein, Fc Tag (MALS verified) |
|
||
ILR-H52H4 | Human | Human IL-23 R Protein, His Tag (MALS & SPR verified) |
|
||
ILR-M5251 | Mouse | Mouse IL-23 R Protein, Fc Tag |
|
Captured Human IL-23 R, Fc Tag (Cat. No. ILR-H5254) on CM5 chip via anti-human IgG Fc antibodies surface can bind Human IL23A & IL12B, His Tag (Cat. No. ILB-H52W5)with an affinity constant of 5.36 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) captured on Biotin CAP - Series S sensor Chip can bind Human IL-23 R, His Tag (SPR verified) (Cat. No. ILR-H52H4) with an affinity constant of 3.39 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
PN-235 | JNJ-77242113; PN-235; JNJ-2113; PN-21235; JNJ-77242113-AAC | Phase 3 Clinical | Protagonist Therapeutics Inc | Psoriasis; Colitis, Ulcerative; Plaque psoriasis | Details |
PN-232 | PN-232; JNJ75105186 | Phase 1 Clinical | Protagonist Therapeutics Inc | Details | |
PN-235 | JNJ-77242113; PN-235; JNJ-2113; PN-21235; JNJ-77242113-AAC | Phase 3 Clinical | Protagonist Therapeutics Inc | Psoriasis; Colitis, Ulcerative; Plaque psoriasis | Details |
PN-232 | PN-232; JNJ75105186 | Phase 1 Clinical | Protagonist Therapeutics Inc | Details |
This web search service is supported by Google Inc.